
Xueyuan Liu
Articles
-
Nov 29, 2024 |
mdpi.com | Yiwu Liu |Xueyuan Liu |Jinghua Tan |Jie Huang
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
-
Nov 25, 2024 |
bmcgenomics.biomedcentral.com | Chengliang Yang |Changhui Liu |Xiaohui Chen |Xueyuan Liu |Meiyun He |Guanglin He | +5 more
The mean DOC (mean ± SD) for 114 InDels was 188,137 ± 87,093 × . Among the 77 A-InDels, the average DOC was 1896 ± 1328 × , with extremes observed at rs34076006 (9971 ± 6867 ×) and rs5787309 (614 ± 290 ×). For the 32 X-InDels in females, the mean DOC was 1936 ± 874 × , with rs16367 displaying the highest value (4208 ± 1345 ×) and rs58595330 the lowest (870 ± 453 ×).
-
Oct 13, 2024 |
dialnet.unirioja.es | Xueyuan Liu |Yan Yu |Xiaolan Fu |Gexuan Song
Ayuda Buscar en la ayuda Buscar en la ayuda Green innovation drives globalization: a longitudinal case study of Angel Yeast’s evolution from a start-up to a world-class manufacturer Autores: Xueyuan Liu, Yan Yu, Gexuan Song, Xiaolan Fu Localización: Journal of evolutionary studies in business, ISSN-e 2385-7137, Vol. 9, Nº. 2, 2024, págs.
-
Aug 31, 2024 |
mdpi.com | Siyu Xiang |Zhengwei Chang |Xueyuan Liu |Lei Luo
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
-
May 21, 2024 |
biorxiv.org | Robert Davidson |Xueyuan Liu |Anna R. Sternberg |Cristina Martos-Rus
AbstractDurable factor VIII (FVIII) expression that normalizes hemostasis is an unrealized goal of hemophilia A adeno-associated virus (AAV)-mediated gene therapy. Trials with initial normal FVIII activity observed unexplained year-over-year declines in expression while others reported low-level, stable FVIII expression inadequate to restore normal hemostasis.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →